

Hiroyuki Suzuki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8322105/publications.pdf>

Version: 2024-02-01

17
papers

206
citations

1306789

7
h-index

1058022

14
g-index

17
all docs

17
docs citations

17
times ranked

311
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust Effect of Hepatic Arterial Infusion Chemotherapy, and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease: A Case Report. <i>Internal Medicine</i> , 2022, , .	0.3	2
2	A Case of TAFRO Syndrome that Responded to Prednisolone-only Treatment: Evaluating Changes in IL-6. <i>Internal Medicine</i> , 2022, , .	0.3	1
3	DNA Methylation in Noncancerous Liver Tissues as Biomarker for Multicentric Occurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma. , 2022, 1, 555-562.		0
4	Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 2594-2604.	2.0	3
5	Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 766-773.	0.9	3
6	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 646.	1.7	19
7	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 987.	1.0	7
8	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. <i>Cancers</i> , 2021, 13, 2786.	1.7	44
9	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. <i>Cancers</i> , 2021, 13, 4450.	1.7	10
10	Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. <i>Translational Oncology</i> , 2021, 14, 101201.	1.7	4
11	Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors. <i>Japanese Journal of Radiology</i> , 2021, , 1.	1.0	1
12	Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 558-565.	0.9	9
13	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. <i>Cancers</i> , 2020, 12, 1010.	1.7	42
14	Promotion of liver regeneration and anti-fibrotic effects of the $\text{ATGF}\alpha^2$ receptor kinase inhibitor galunisertib in CCl ₄ -treated mice. <i>International Journal of Molecular Medicine</i> , 2020, 46, 427-438.	1.8	13
15	Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. <i>Oncology Letters</i> , 2020, 20, 2257-2265.	0.8	44
16	A long-term survival case of advanced hepatocellular carcinoma treated with multidisciplinary therapies with progression to hepatic arterial infusion chemotherapy and hepatectomy. <i>Acta Hepatologica Japonica</i> , 2020, 61, 418-425.	0.0	0
17	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. <i>Oncology</i> , 2019, 96, 192-199.	0.9	4